Navigation Links
Watson Launches Generic AMRIX®
Date:5/16/2011

PARSIPPANY, N.J., May 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Pharma, Inc., has launched an authorized generic version of AMRIX® (Cyclobenzaprine Hydrochloride Extended-Release Capsules) 15 mg and 30 mg, as part of an agreement with Anesta AG, a subsidiary of Cephalon, Inc.  AMRIX is approved for use along with rest and physical therapy to help control muscle spasm associated with acute, painful musculoskeletal conditions.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Under the terms of the non-exclusive sales agent agreement, Anesta manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States on behalf of Anesta and will receive payments based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending March 31, 2011, AMRIX had sales of approximately $125 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.  

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

AMRIX® is a registered trademark of Cephalon, Inc.  CONTACTS: Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Concerta®
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
3. Watson First Quarter 2011 Net Revenue Increases to $877 Million
4. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
5. Watson Confirms Welchol® Patent Challenge
6. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
7. Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
8. Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
9. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
10. Watson Confirms OxyContin® Patent Challenge
11. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive who has ... medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and Stryker. ... building successful businesses in the sector and has worked in ... North America . ... Educated at the University of Edinburgh (Dental Surgery), University ...
(Date:1/16/2017)... Tenn. , Jan. 16, 2017  Cumberland Pharmaceuticals ... of Kenneth J. Krogulski , CFA to its ... Executive Officer of Berkshire Asset Management LLC . ... a 30-year-old independent SEC registered investment advisory firm with ... has over 37 years, experience in security analysis and ...
(Date:1/15/2017)... 14, 2017 ImmersiveTouch Inc., the global leader ... announced recent appointments strengthening their Executive Management team.  ... as Chief Executive Officer, Jay Banerjee as ... President of Sales and Jia Luo , PhD ... Mr. Bowman has 20 years experience commercializing ...
Breaking Medicine Technology:
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... ... manuscript in the Aesthetic Surgery Journal , the official journal of The ... conducted on lower eyelid retraction surgery. The procedure is designed to correct drooping, ...
(Date:1/16/2017)... ... , ... NexTec Group has been selected as a member of the Bob ... in the field of midmarket financial software. , Members of the VAR Stars were ... not based on revenue and those firms chosen represent a wide range of size ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow production ... said Christina Austin - CEO of Pixel Film Studios. , On Tour’s new ... style and animation of their slideshows. Place each slide on top of another slide ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
(Date:1/13/2017)... , ... January 13, 2017 , ... The 18th European ... America hotel on March 3-4, 2017. This Congress is expertly designed to meet ... management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor ...
Breaking Medicine News(10 mins):